Potential new treatment for soft tissue sarcoma

Posted on:

The FDA recently granted orphan drug status to CPI-613 (devimistat) for the treatment of soft tissue sarcoma. The maker, Rafael Pharmaceuticals, launched a phase 1/2 clinical for patients with relapsed/refractory soft tissue sarcoma.

Read more about it here